Enliven Therapeutics (NASDAQ:ELVN) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of Enliven Therapeutics (NASDAQ:ELVN) from a sell rating to a hold rating in a research note published on Saturday.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $41.20.

Enliven Therapeutics Stock Up 8.9%

Shares of Enliven Therapeutics stock traded up $1.80 on Friday, hitting $22.07. 565,729 shares of the company’s stock traded hands, compared to its average volume of 589,594. The stock has a market cap of $1.31 billion, a P/E ratio of -11.99 and a beta of 0.80. The firm’s 50-day moving average is $20.23 and its 200 day moving average is $20.08. Enliven Therapeutics has a 52-week low of $13.30 and a 52-week high of $26.48.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.11. Equities research analysts forecast that Enliven Therapeutics will post -1.95 EPS for the current year.

Insider Transactions at Enliven Therapeutics

In other news, insider Joseph P. Lyssikatos sold 12,500 shares of the firm’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $22.08, for a total value of $276,000.00. Following the transaction, the insider directly owned 915,188 shares in the company, valued at $20,207,351.04. This trade represents a 1.35% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Benjamin Hohl sold 3,250 shares of the company’s stock in a transaction that occurred on Monday, September 29th. The shares were sold at an average price of $20.40, for a total value of $66,300.00. Following the sale, the chief financial officer directly owned 23,000 shares in the company, valued at approximately $469,200. This represents a 12.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 99,984 shares of company stock worth $2,021,749 in the last ninety days. 25.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Several institutional investors have recently made changes to their positions in the company. Invesco Ltd. increased its position in shares of Enliven Therapeutics by 4.3% during the 2nd quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock worth $440,000 after purchasing an additional 913 shares in the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock valued at $75,000 after purchasing an additional 930 shares during the period. Quantbot Technologies LP boosted its holdings in Enliven Therapeutics by 47.1% during the 2nd quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock worth $90,000 after acquiring an additional 1,434 shares during the last quarter. Legal & General Group Plc raised its holdings in Enliven Therapeutics by 4.8% during the 3rd quarter. Legal & General Group Plc now owns 33,765 shares of the company’s stock valued at $691,000 after acquiring an additional 1,540 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Enliven Therapeutics by 8.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,729 shares of the company’s stock worth $428,000 after acquiring an additional 1,693 shares in the last quarter. 95.08% of the stock is currently owned by institutional investors and hedge funds.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.